Aktienanalyse zu NRX Pharmaceuticals Inc (NRXP)NRXPNRX Pharmaceuticals Inc

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

NRX Pharmaceuticals Inc is a good buy right now due to its current price of $3.55, which is significantly lower than analyst price targets of $34 and $49, suggesting a potential upside of 854% and 1,382% respectively. Additionally, the company has shown a gross margin of 54.22% in Q4 2025, indicating improving profitability. The main risk is the recent quarterly loss of $0.18 per share, which was worse than expected, reflecting ongoing challenges in profitability.